中国经济网北京10月14日讯 亚太药业（002370.SZ）今日复牌一字涨停，截至发稿，报6.24元，涨 幅10.05%。 本次向特定对象发行股票的发行对象为新控股股东星浩控股，因此本次发行构成关联交易。 截至预案公告日，公司现控股股东为富邦集团，实际控制人为宋汉平、傅才、胡铮辉组成的管理团 队，富邦集团及汉贵投资合计持有公司108,945,566股股份，占公司总股本的14.61%。 2025年10月13日，星浩控股与公司签订附条件生效的《股份认购协议》。同时，公司现控股股东富 邦集团及汉贵投资与星浩控股及星宸投资签署了《股份转让协议》；星浩控股与星宸投资签署了《一致 行动人协议》《表决权委托协议》。 亚太药业昨日晚间披露《2025年度向特定对象发行股票预案》《关于筹划公司控制权变更事项进展 暨公司股票复牌的公告》等公告。 2025年10月13日，公司控股股东富邦集团及一致行动人汉贵投资与浙江星浩控股合伙企业（有限合 伙）（以下简称"星浩控股"）及一致行动人浙江星宸股权投资合伙企业（有限合伙）（以下简称"星宸 投资"）签署了《股份转让协议》。富邦集团和汉贵投资拟通过协议转让方式转让公司14.62%股份，共 计 ...

Market Overview - The Shanghai Composite Index closed at 3897.56 points, up 0.21%, while the Shenzhen Component Index closed at 13096.03 points, down 1.02%. The ChiNext Index fell by 2.24%, and the STAR Market 50 Index decreased by 2.84% [1] - Among the tradable A-shares, 2248 stocks rose (43.68%), while 2747 stocks fell, and 152 stocks remained flat. There were 42 stocks that hit the daily limit up, and 3 stocks hit the limit down [1] Top Performing Stocks - The leading sectors for stocks hitting the daily limit up were Electronics, Light Industry Manufacturing, and Coal, with 4, 4, and 3 stocks respectively [1] - Notable stocks hitting the limit up include *ST Guohua and *ST Wanfang, with *ST Dongyi achieving 6 consecutive limit up days, the highest among all [1] - The stock with the highest limit up order volume was Shanzi Gaoke, with 10523.95 million shares, followed by Chuangjiang New Materials and Yatai Pharmaceutical with 7407.32 million shares and 7161.61 million shares respectively [1] Limit Up Stocks Summary - The top limit up stocks by closing price and order volume include: - Antai Technology (19.86 CNY, 4326.27 thousand shares, 85919.72 million CNY) in Nonferrous Metals - Chuangjiang New Materials (11.32 CNY, 7407.32 thousand shares, 83850.83 million CNY) in Nonferrous Metals - Dongxin Peace (25.28 CNY, 2188.46 thousand shares, 55324.35 million CNY) in Communications [1] - Other notable limit up stocks include: - Shanzi Gaoke (4.74 CNY, 10523.95 thousand shares, 49883.52 million CNY) in Automotive - Yatai Pharmaceutical (6.24 CNY, 7161.61 thousand shares, 44688.45 million CNY) in Pharmaceutical Biology [1] Additional Limit Up Stocks - Other stocks with significant limit up performance include: - Yuyuan Co. (14.87 CNY, 1828.23 thousand shares, 27185.81 million CNY) in Comprehensive - Hefei Urban Construction (11.14 CNY, 2412.43 thousand shares, 26874.45 million CNY) in Real Estate - New Agricultural Shares (21.86 CNY, 1215.81 thousand shares, 26577.54 million CNY) in Basic Chemicals [1][2]

Core Viewpoint - Asia-Pacific Pharmaceutical (亚太药业) announced a share transfer agreement involving its controlling shareholder, Ningbo Fubon Group (富邦集团), which will transfer 14.61% of its shares to Zhejiang Xinghao Holdings (星浩控股) for a total of 900 million yuan at a price of 8.26 yuan per share, changing the controlling shareholder and actual controller to Qiu Zhongxun [1][2] Group 1 - The share transfer involves a total of 108,945,566 shares, which represents 14.61% of Asia-Pacific Pharmaceutical's total shares [1] - The transaction will be executed in five installments, with performance commitments from the transferor to ensure that the company's main business revenue in 2025 will not be less than 360 million yuan, and the net profit loss will not exceed 70 million yuan [1] - If the performance commitments are not met, the transferor will compensate the acquirer as per the agreement [1] Group 2 - Xinghao Holdings will directly acquire 60,525,314 shares (8.12% of total shares), while its action-in-concert party, Xingchen Investment (星宸投资), will acquire 48,420,252 shares (6.49% of total shares) [2] - To ensure stable control, Xingchen Investment will delegate all voting rights of its shares to Xinghao Holdings [2] - Asia-Pacific Pharmaceutical also plans to raise up to 700 million yuan through a private placement to Xinghao Holdings for new drug research and development, with a share price of 5.11 yuan and a maximum issuance of 136,986,301 shares [2] Group 3 - The company currently focuses on chemical generic drugs and faces performance pressure due to national centralized procurement and consistency evaluation policies, indicating a pressing need for business transformation [2] - The fundraising project is a key step in implementing the company's "combination of imitation and innovation, innovation-driven" development strategy, aimed at optimizing product structure and enhancing core competitiveness and profitability [2] - Xinghao Holdings was established on July 3, 2025, and its actual controller, Qiu Zhongxun, also controls the domestic pharmaceutical e-commerce platform "Yao Dou Technology" (药兜科技), which collaborates with over 4,000 upstream pharmaceutical companies and approximately 650,000 downstream commercial and terminal customers [2]

南方财经10月14日电，亚太药业(002370.SZ)于2025年10月14日发布公告，公司控股股东宁波富邦控股 集团有限公司及其一致行动人上海汉贵投资管理有限公司，已于10月13日与浙江星浩控股合伙企业（有 限合伙）及其一致行动人浙江星宸股权投资合伙企业（有限合伙）签署了《股份转让协议》。此次交易 涉及亚太药业14.61%的股份，共计108,945,566股，转让价格确定为每股8.26元，交易总金额达约9亿元 人民币。若交易最终顺利完成，亚太药业的控股股东将由富邦集团变更为星浩控股，公司实际控制人也 将由宋汉平、傅才、胡铮辉等组成的管理团队变更为邱中勋。 转让方富邦集团及汉贵投资承诺，亚太药业2025年度经审计的主营业务收入（扣除无关收入及不具备商 业实质的收入后）将不低于3.6亿元。同时，公司2025年扣除非经常性损益后的净利润，其亏损下限被 设定为7000万元。此外，对于资产质量，转让方承诺截至2025年12月31日，公司的应收账款余额不高于 1.4亿元，并确保在2026年4月25日前，该部分应收账款的回收率超过70%，且坏账率不超过3%。 同日公司公布定增预案，拟发行数量不超过1.37亿股（含本数）， ...

Core Viewpoint - The controlling shareholder of Asia-Pacific Pharmaceutical will change from Fubon Group to Xinghao Holdings, with the stock resuming trading on October 14, 2025 [2][5]. Shareholder Change - Fubon Group and Hangu Investment plan to transfer 14.62% of shares, totaling 108.9 million shares, at a price of 8.26 CNY per share, amounting to 900 million CNY [4]. - After the transfer, the controlling shareholder will be Xinghao Holdings, and the actual controllers will change to Qiu Zhongxun [4]. Corporate Restructuring - Asia-Pacific Pharmaceutical's board approved the dissolution of its wholly-owned subsidiary, Wuhan Guanggu Asia-Pacific Pharmaceutical, to optimize organizational structure and improve operational efficiency [5]. - The subsidiary will no longer be included in the consolidated financial statements after the dissolution [5]. Fundraising and Investment - The company announced a targeted fundraising plan to issue up to 137 million shares at a price of 5.11 CNY per share, raising a total of up to 700 million CNY [7]. - The funds will be used for new drug research and development projects, including oncolytic virus drug platforms and long-acting formulations [7][8]. - The issuance will not change the company's control but may dilute net asset returns and earnings per share in the short term [7]. Strategic Direction - The company aims to transition from traditional chemical generics to improved new drugs and innovative drug research, enhancing its risk resistance and expanding its product portfolio [8].

消息面上，亚太药业发布公告称，10月13日，公司控股股东富邦集团及一致行动人汉贵投资与浙江星浩 控股合伙企业（有限合伙）（以下简称"星浩控股"）及一致行动人浙江星宸股权投资合伙企业（有限合 伙）签署了《股份转让协议》。富邦集团和汉贵投资拟通过协议转让方式转让公司14.62%股份，转让 价格为8.26元/股，合计总金额为9亿元。本次协议转让完成后，公司的控股股东将由富邦集团变更为星 浩控股，公司的实际控制人将由宋汉平、傅才、胡铮辉组成的管理团队变更为邱中勋。 北京商报讯（记者 丁宁）10月14日，亚太药业（002370）以涨停开盘，开盘价为6.24元/股，涨幅为 10.05%。 ...

Core Viewpoint - Fubon Group and its concerted parties have sold all their shares in Asia-Pacific Pharmaceutical after more than three years of control, transferring a total of 14.62% of the company's shares to Xinghao Holdings and its concerted party, with a significant premium over the previous trading price [1][2]. Group 1: Share Transfer Details - Fubon Group and Hangu Investment signed a share transfer agreement to transfer approximately 109 million shares at a price of 8.26 CNY per share, totaling 900 million CNY [1]. - Xinghao Holdings will acquire 60.53 million shares, while Xingchen Investment will acquire 28.89 million shares and 19.53 million shares from Fubon Group and Hangu Investment, respectively [1]. Group 2: Changes in Control - Following the transfer, the controlling shareholder of Asia-Pacific Pharmaceutical will change from Fubon Group to Xinghao Holdings, with the actual controllers shifting from a management team to Qiu Zhongxun, the ultimate beneficiary of Xinghao Holdings [1]. - Asia-Pacific Pharmaceutical will issue approximately 137 million shares to Xinghao Holdings, resulting in a total holding of about 198 million shares, representing 22.38% of the company [4]. Group 3: Financial Performance - Asia-Pacific Pharmaceutical has faced financial challenges, with cumulative non-recurring net losses exceeding 2.5 billion CNY from 2019 to 2024 [4]. - In the first half of 2025, the company reported revenue of approximately 15.2 million CNY, a year-on-year decline of 31.48%, while the net profit attributable to shareholders increased by 1820.97% to approximately 10.5 million CNY, despite a non-recurring net loss of 48.86 million CNY [4].

Core Viewpoint - The controlling shareholder of Asia-Pacific Pharmaceutical will change from Fubon Group to Xinghao Holdings, with the stock resuming trading on October 14, 2025 [1][3]. Shareholder Control Change - Fubon Group and Hangu Investment plan to transfer 14.62% of the company's shares, totaling 108.9 million shares, at a price of 8.26 CNY per share, amounting to a total of 900 million CNY [2]. - Following the transfer, the controlling shareholder will shift to Xinghao Holdings, and the actual controller will change to Qiu Zhongxun [2]. Stock Resumption and Subsidiary Deregistration - Asia-Pacific Pharmaceutical's stock will resume trading on October 14, 2025 [3]. - The company has approved the deregistration of its wholly-owned subsidiary, Wuhan Optics Valley Asia-Pacific Pharmaceutical Co., Ltd., which will no longer be included in the consolidated financial statements after deregistration [3]. Fundraising and Investment Plans - The company plans to issue up to 137 million shares at a price of 5.11 CNY per share, raising a total of no more than 700 million CNY for new drug research and development projects [4]. - The fundraising will focus on developing oncolytic virus drug platforms, long-acting formulations, and compound formulations, among others [4]. - The issuance will not change the company's control but will increase total share capital and net assets, potentially diluting net asset returns and earnings per share in the short term [4]. Strategic Transition - Through the implementation of the fundraising projects, the company aims to transition from a focus on traditional chemical generics to improved new drugs and first-class innovative drug research and development [5]. - This strategic shift is intended to enhance the company's operational resilience and advance promising new drug projects into critical clinical stages, thereby broadening its product portfolio [5].

Core Viewpoint - The transfer of 14.61% of shares in Asia-Pacific Pharmaceutical (002370) at a premium of 45.68% raises questions about the future direction of the company, which has reported six consecutive years of net profit losses excluding non-recurring items [2][5]. Group 1: Share Transfer Details - Asia-Pacific Pharmaceutical announced that its controlling shareholder, Fubon Group, will transfer 14.61% of its shares to Xinghao Holdings at a price of 8.26 yuan per share, totaling 900 million yuan [5]. - The transfer price represents a 45.68% premium compared to the last trading price of 5.67 yuan per share before suspension on September 26 [5]. Group 2: Financial Performance - The company has reported net profit losses excluding non-recurring items for six consecutive years, with figures from 2019 to 2024 being -1.94 billion yuan, -143 million yuan, -239 million yuan, -117 million yuan, -68.94 million yuan, and -28.13 million yuan respectively [5]. - In the first half of 2025, the company achieved revenue of approximately 152 million yuan, a year-on-year decrease of 31.48%, while the net profit attributable to shareholders was approximately 105 million yuan, an increase of 1820.97% due to the sale of a subsidiary [6]. Group 3: New Leadership and Future Plans - After the share transfer, the actual controller will change to Qiu Zhongxun, who is associated with Yaodou Technology, a digital pharmaceutical platform with extensive industry connections [8]. - The company plans to raise up to 700 million yuan by issuing shares at 5.11 yuan each, with proceeds dedicated to new drug research and development [8]. - Yaodou Technology's collaboration with over 1,000 pharmaceutical companies and its extensive supply chain capabilities are expected to enhance the company's innovation and market competitiveness [8].

Group 1 - Salt Lake Co. expects net profit for the first three quarters of 2025 to be between 4.3 billion and 4.7 billion yuan, representing a year-on-year increase of 36.89% to 49.62% [1][2] - The increase in profit is attributed to the rise in potassium chloride prices compared to the previous year, which boosted profitability in that segment [1] - Lithium carbonate market prices have seen a downward adjustment, but overall performance remains positive compared to the previous year [1] Group 2 - Lingyi Technology anticipates net profit for the first three quarters of 2025 to be between 1.89 billion and 2.12 billion yuan, reflecting a growth of 34.10% to 50.42% year-on-year [4][5] - The growth is driven by the launch of new AI terminal products and increased production capacity [5] Group 3 - Xinhua Insurance projects net profit for the first three quarters of 2025 to be between 29.986 billion and 34.122 billion yuan, an increase of 45% to 65% year-on-year [7] - The growth is attributed to improved asset allocation and a favorable capital market environment, leading to significant investment income [7] Group 4 - Sanmei Co. expects net profit for the first three quarters of 2025 to be between 1.524 billion and 1.646 billion yuan, indicating a year-on-year increase of 171.73% to 193.46% [22] - The increase is driven by the reduction in production quotas for certain refrigerants and rising market prices [22] Group 5 - Flying Technology anticipates net profit for the first three quarters of 2025 to be between 275 million and 300 million yuan, representing a growth of 110.80% to 129.96% year-on-year [24] - The growth is supported by increased investment in cutting-edge fields and a recovery in consumer electronics demand [24] Group 6 - Northern Rare Earth received a warning letter from the Inner Mongolia Securities Regulatory Bureau for failing to disclose related party non-operating fund occupation [6] - The company incurred costs related to employee salaries and benefits post-acquisition, which were not disclosed as required [6] Group 7 - Gansu Energy expects net profit for the first three quarters of 2025 to be between 1.55 billion and 1.6 billion yuan, reflecting a year-on-year increase of 11.86% to 15.47% [29] - The increase is attributed to a decrease in power generation costs compared to the previous year [29] Group 8 - Dongfang Tower anticipates net profit for the first three quarters of 2025 to be between 750 million and 900 million yuan, indicating a growth of 60.83% to 93% year-on-year [30] - The growth is driven by stable production in potassium chloride and rising market prices [30]